Description
Title: A Phase II Single-Centre Randomized Study in the Ivory Coast Examining the Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease
Abstract: Background. Patients with sickle cell disease frequently require hospitalization due to vaso-occlusive crisis (VOC). Intravenous morphine or nonsteroidal anti-inflammatory drugs (NSAIDs), which have a variety of dose-related side effects, are the mainstays of treatment. The effectiveness of vascular electrical stimulation therapy (VEST) on VOCs is a matter of debate. Objective. to assess VEST’s efficiency and safety in cutting the median amount of time spent in severe VOC. Methods. A phase II, single-blinded, randomized, controlled, triple-arm, comparative trial was carried out. Thirty (30) adult patients with a severe vaso-occlusive crisis were included. 20 patients were divided equally into two interventional arms: 10 patients received VEST + Analgesics + Hydration (group 1), while the remaining 10 patients received VEST + Analgesics + Hydration + NSAIDs. Our control group (group 0) consisted of 10 patients receiving conventional therapy (Analgesics + Hydration + NSAIDs) (group 2). The median time to severe crisis elimination served as the primary efficacy endpoint. Secondary endpoints included median tramadol consumption, haemoglobin level progression over a 3-day period, side effects, and treatment failure. Results. 23 women, whose ages ranged from 14 to 37, were present. We found that the VEST had a positive effect on the median time to severe crisis (VAS greater than 2) elimination, which was 17 hours in group 1 compared to 3.5 hours in group 2 and 4 hours in group 3, with a p value of 0.0166. Patients in the interventional arms experienced similar statistically significant reductions in the overall duration of the crisis (VAS over 0) and median tramadol consumption. Conclusion: These statistically significant findings in the interventional groups point to VEST as a potential treatment option for sickle cell patients with VOC.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.